STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data | Zendy

Zhenxin Wang | Zendy; Guoqing Zhang | Zendy; Zhongcheng Li | Zendy; Jin Li | Zendy; Hongbo Ma | Zendy; Ailian Hei | Zendy; Shunchang Jiao | Zendy; Yi Hu | Zendy; Shengjie Sun | Zendy; Liangliang Wu | Zendy; Ji Zhou | Zendy; Yu Wang | Zendy; Ellen He | Zendy; Sven Skog | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data

Author(s) -

Zhenxin Wang,

Guoqing Zhang,

Zhongcheng Li,

Jin Li,

Hongbo Ma,

Ailian Hei,

Shunchang Jiao,

Yi Hu,

Shengjie Sun,

Liangliang Wu,

Ji Zhou,

Yu Wang,

Ellen He,

Sven Skog

Publication year - 2020

Publication title -

future science oa

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.825

H-Index - 23

ISSN - 2056-5623

DOI - 10.2144/fsoa-2020-0130

Subject(s) - biomarker , lung cancer , carcinoma , oncology , medicine , lung , pathology , cancer research , biology , genetics

Aim: A prospective investigation of serum thymidine kinase 1 concentration (STK1p) was performed to evaluate its prognostic value in patients with non-small-cell lung carcinoma (NSCLCs).Patients & methods: The STK1p values of 127 patients were determined by an enhanced chemiluminescent dot blot assay. The patients were recruited from March 2011 to December 2017. Results: Kaplan–Meier plot showed that patients with elevated STK1p values had worse overall survival (OS), especially patients of early/middle stages. Multi-variable COX regression showed that STK1p value and combined treatment surgery + chemotherapy were independent prognostic factors for favorable OS. Conclusion: STK1p is helpful in predicting OS of early/middle stages (I–IIIA) NSCLCs patients following a nonrandomized individual adapted treatment, but is may be not recommended in advanced stages (IIIB + IV) of NSCLCs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research